TECH Relative Valuation
TECH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TECH is overvalued; if below, it's undervalued.
Historical Valuation
Bio-Techne Corp (TECH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 27.15 is considered Undervalued compared with the five-year average of 43.36. The fair price of Bio-Techne Corp (TECH) is between 62.74 to 94.81 according to relative valuation methord. Compared to the current price of 54.14 USD , Bio-Techne Corp is Undervalued By 13.7%.
Relative Value
Fair Zone
62.74-94.81
Current Price：54.14
13.7%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
4.23
P/B
Median3y
5.96
Median5y
7.44
2.59
FCF Yield
Median3y
2.14
Median5y
1.94
Competitors Valuation Multiple
The average P/S ratio for TECH's competitors is 6.16, providing a benchmark for relative valuation. Bio-Techne Corp Corp (TECH) exhibits a P/S ratio of 6.75, which is 9.56% above the industry average. Given its robust revenue growth of 4.20%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Bio-Techne Corp (TECH) currently overvalued or undervalued?
What is Bio-Techne Corp (TECH) fair value?
How does TECH's valuation metrics compare to the industry average?
What is the current P/B ratio for Bio-Techne Corp (TECH) as of Jul 13 2025?
What is the current FCF Yield for Bio-Techne Corp (TECH) as of Jul 13 2025?
What is the current Forward P/E ratio for Bio-Techne Corp (TECH) as of Jul 13 2025?